Select a medication above to begin.
Ivra
melphalan
Black Box Warnings .
Myelosuppression
severe myelosuppression leading to infection or bleeding may occur; incr. myelosuppression with IV formulation compared to oral formulation; monitor CBC with diff
Hypersensitivity Reaction
have occurred in 2% of patients receiving IV formulation, including anaphylaxis; D/C for serious hypersensitivity reaction
Secondary Malignancy
produces chromosomal aberrations in vitro and in vivo, thus consider potentially leukomogenic in humans
Adult Dosing .
Dosage forms: INJ
Special Note
- [uses, dosing may vary]
- Info: refer to institution protocols and pkg insert prior to prescribing for uses, premeds, and dosing including toxicity-related dose adjustments
multiple myeloma, palliative tx
- [16 mg/m^2/dose IV x1 on day 1 of 28-day cycle, starting cycle 5]
- Start: 16 mg/m^2/dose IV x1 on day 1 of 14-day cycle x4 cycles
renal dosing
- [see below]
- CrCl 10-50: decr. usual dose by 25%; CrCl <10: decr. usual dose by 50%
- HD: decr. usual dose by 50%, on dialysis days administer after dialysis; no supplement; PD: decr. usual dose by 50%; no supplement
hepatic dosing
- [not defined]
Peds Dosing .
Peds dosing is currently unavailable or not applicable for this drug.